Andrew Schultz

This is applicable even in pharma! Saw a stat that said patients view doctors as their most trusted information source. This may be true overall, but segment your audiences. This is not true for some segments, including Black patients. Research says otherwise and as a Black patient, I concur. Al is fantastic and his perspective is spot on, especially for segments like your Black patients. Black consumers are 59% more likely to try a brand that they feel is speaking directly to them and that they connect with. That connection cannot happen if we apply an overall patient lens bc our population is too small to change the overall lens. #pharmamarketing #hypersegmentation #diversitymatters

6

3 Comments

Day One Digital Pharma Series 2024: Insights, Innovation… and Puppies? Greetings from Philly! Day one of #DigitalPharmaEast has been nothing short of eventful. Between everyone glued to the debate, a visit to the Liberty Bell, and yes — even puppies - great idea from GoodRx!! — the day was packed with action and insights. BUT...the focus is clear—innovation in pharma marketing is no longer a luxury, it’s a necessity. The discussions revolved around how data, AI, and digital transformation are driving unprecedented change in how we connect with HCPs and patients. A few key takeaways: Data-Driven Personalization: There was a strong emphasis on using real-time data to create hyper-personalized campaigns that deliver the right message at the right moment, without losing sight of compliance. A continued balance. AI’s Growing Role: From content generation to predictive analytics, AI was a big focus, especially in how it’s reshaping everything from drug launches to patient engagement. Pharma is starting to see the transformative potential of machine learning to drive both efficiency and impact. OmniEVERYTHING: Breaking down silos across digital, social, and traditional media was a recurring theme. The conversation has shifted from being present in multiple channels to creating truly connected experiences that drive outcomes. Compliance and Innovation Must Coexist: A critical theme was that while pharma marketing is innovating rapidly, keeping a sharp focus on regulatory compliance is more important than ever. The challenge is balancing bold ideas with tight regulations. It’s clear that the pace of change is accelerating, and those who can EAT, SLEEP, DREAM IN digital transformation will be the ones who win in the pharma space. Excited for what the rest of the conference holds! #PharmaMarketing #DigitalTransformation #AIinPharma #MediaInnovation #CMO #HealthcareMarketing Butler/Till

40

1 Comment

Thoughts on this? >> Children’s Hospital of Philadelphia Researchers Announce New AI Model for Cell Segmentation and Classification >> Comment below! >>> lqventures.com #mhealth #IoT #industry40 #healthtech #AI

3

"When digital transformation is done right, it's like a caterpillar turning into a butterfly, but when it is done wrong, all you have is a really fast caterpillar," says author and MIT lecturer George Westerman. A great first step to "being the butterfly" are the insights that Megan Jones and Uttama Rath share below. ⬇

13

A B2i Digital Featured Company, Evoke Pharma (Nasdaq: EVOK), and EVERSANA, Evoke’s commercialization partner, announced statistically significant findings from real-world data on GIMOTI® (metoclopramide) nasal spray. The study, presented at the 2024 American College of Gastroenterology (ACG) Annual Scientific Meeting, demonstrates the potential of Gimoti as a supportive care option for patients taking GLP-1 receptor agonists. GLP-1 medications, commonly prescribed for type 2 diabetes, can exacerbate gastrointestinal issues, including gastroparesis, due to delayed gastric emptying. The GIMOTI study compared patients treated with nasal metoclopramide (NMCP) to those on oral metoclopramide (OMCP) and focused on those with prior GLP-1 prescriptions. Evoke’s Key Study Findings Presented at ACG 2024 (within a 6-month index period): - 91% reduction in all-cause emergency department visits (p=0.001) for patients using Gimoti versus oral metoclopramide - 89% reduction in outpatient hospital visits (p=0.032) - 41% fewer all-cause office visits (p=0.027) - Significant reductions observed in diabetic gastroparesis-related healthcare utilization The submission received the Presidential Poster Award, placing it among the top 5% of data accepted to the conference, and was selected as the Outstanding Research Award in the Stomach Category. Evoke’s CEO, Matt D'Onofrio, commented: “This data is particularly encouraging given the rising number of patients using GLP-1 agonists for diabetes, many of whom also suffer from gastroparesis. Our goal is to provide data regarding Gimoti as supportive care for diabetic gastroparesis for those also on GLP-1 agonists. This study, combined with the earlier real-world data presented at key conferences, reinforces GIMOTI’s potential to improve outcomes for patients and reduce the overall financial burden on the healthcare system.” To see the full details, please visit Evoke Pharma's Press Release. https://lnkd.in/ePuqdd9d The results presented at ACG 2024 build on earlier data showing GIMOTI’s ability to significantly reduce healthcare resource utlization (HRU) for patients with diabetic gastroparesis. Similar results were previously presented at Digestive Disease Week (DDW) 2024 and ACG 2023, reinforcing the value of GIMOTI compared to oral metoclopramide. Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents, resulting in severe GI symptoms and systemic complications. The gastric delay caused by gastroparesis can compromise the absorption of orally administered medications. Metoclopramide remains the only drug currently approved in the United States to treat gastroparesis. Before FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations. To learn more about Evoke Pharma’s recent developments and its approach to treatment visit https://evokepharma.com.

25

Thoughts on this? >> GP out of hours service BrisDoc to deploy EPM system >> Comment below! >>> lqventures.com #digitalhealth #socialmedia #digitalmarketing #IoT #mhealth #healthtech #AI #industry40

1

CDMO Marketers: To what extent are you delivering messages to your audiences about these various market dynamics? Industry trends and challenges represent marketing opportunities. Opportunities to tell your prospects and clients how you are distinctly addressing each trend and ultimately alleviating their concerns. #cdmo #pharma #manufacturing #pharmaceutical #marketing

4

We've seen a lot of changes in the healthcare marketing this year: AI for personalization, video for engagement, and the growing importance of meticulous reputation management. Check out other trends: https://hubs.ly/Q02GfD3g0 #HealthcareMarketing

1